Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference

Anticancer agents that have minimal effects on normal cells and tissues are ideal cancer drugs. Here, we show specific inhibition of human cancer cells carrying oncogenic mutations in the epidermal growth factor receptor (EGFR) gene by means of oncogenic allele-specific RNA interference (RNAi), both...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-08, Vol.8 (8), p.e73214
Main Authors: Takahashi, Masaki, Chiyo, Tomoko, Okada, Takashi, Hohjoh, Hirohiko
Format: Article
Language:English
Subjects:
Alleles
Animals
Anticancer properties
Antitumor agents
Cancer
Cancer prevention
Cancer therapies
Cancer treatment
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Cell Line, Tumor
Deoxyribonucleic acid
DNA
Drugs
Epidermal growth factor
Epidermal growth factor receptors
Epidermal growth factors
ErbB Receptors - genetics
Gene expression
Gene therapy
Genetic aspects
Genetic Therapy
Growth factors
Humans
Information technology services
Inhibition
Interference
Kinases
Laboratory animals
Lung - metabolism
Lung - pathology
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Mice
Mice, Inbred BALB C
Mutation
Neurology
Neurosciences
Penicillin
Psychiatry
Ribonucleic acid
RNA
RNA Interference
RNA, Small Interfering - genetics
RNA, Small Interfering - therapeutic use
RNA-mediated interference
Tissues
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticancer agents that have minimal effects on normal cells and tissues are ideal cancer drugs. Here, we show specific inhibition of human cancer cells carrying oncogenic mutations in the epidermal growth factor receptor (EGFR) gene by means of oncogenic allele-specific RNA interference (RNAi), both in vivo and in vitro. The allele-specific RNAi (ASP-RNAi) treatment did not affect normal cells or tissues that had no target oncogenic allele, whereas the suppression of a normal EGFR allele by a conventional in vivo RNAi caused adverse effects, i.e., normal EGFR is vital. Taken together, our current findings suggest that specific inhibition of oncogenic EGFR alleles without affecting the normal EGFR allele may provide a safe treatment approach for cancer patients and that ASP-RNAi treatment may be capable of becoming a safe and effective, anticancer treatment method.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0073214